For the three months ended Sept. 30, the cannabis company reported a net loss of C$40.7 million, or C$0.10 a share, compared with C$5 million, or C$0.02 a share, a year earlier. Analysts surveyed by FactSet had expected a loss of C$0.04 a share.
Consolidated revenue increased to C$81.4 million, below analysts’ forecast of C$90.1 million. Cannabis revenue climbed 30% to C$66.2 million, with growth across its medical, adult-use and international categories. International sales more than doubled, led by strong medical sales in Germany and Poland.
Revenue from Storz & Bickel, Canopy’s vaporizer and device segment, fell 4% to C$15.1 million amid softer consumer spending.
Comments (0)
No comments yet. Be the first!